Loading…
100% of patients in Cohort 1 achieved the primary efficacy endpoint.
Hoth Therapeutics, a Nasdaq-listed biopharmaceutical company, announced the successful completion of its Phase 2a clinical trial for HT-001, a topical formulation designed to combat skin toxicities associated with cancer treatments. The trial, which involved Cohort 1, reported a 100% success rate in achieving the primary efficacy endpoint.
The announcement highlighted that all patients in Cohort 1 experienced significant relief from skin toxicities, marking a notable advancement in the company's therapeutic pipeline. This breakthrough positions Hoth Therapeutics favorably in the competitive landscape of cancer treatment adjuncts.
As of the latest data, Rocket One Inc. (HOTH) has a free float of 14,960,800 shares and 15,514,300 shares outstanding.
This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.